Namwiwat Medical

Namwiwat Medical Corporation, or NAM, revealed its growth plan under five core strategies during its earnings call for the second quarter of fiscal year 2026. The strategies include expanding its product portfolio to cover the entire value chain from upstream to downstream, building its brand to increase margins and create brand loyalty, expanding into international markets through subsidiaries in Malaysia and Italy, as well as establishing a component assembly base in Indonesia with local partners, using strategic partnerships to develop products, and managing costs efficiently. The company continues to advance medical innovations and health solutions to support the growth of the medical industry, an aging society, and the trend toward treatments that emphasize greater precision and safety.

NAM announced its second-half strategy to expand its portfolio across the entire value chain, from upstream to downstream, while building its brand to increase margins and create brand loyalty. The company is also expanding into international markets through subsidiaries in Malaysia and Italy, and setting up an SKD parts assembly base in Indonesia with a local partner. Meanwhile, EURO reported first-half revenue from sales and services of 749 million baht, up 12.6 percent, and net profit of 87 million baht, up 26.9 percent from the same period last year. The company targets full-year revenue growth of 10 to 15 percent and plans to open the first phase of Euro Creations T3 at the end of this year. DOD announced a revised investment strategy by negotiating to recover deposits and advance payments for some projects in order to manage risk and maintain the highest level of financial liquidity and security.

Namwiwat Medical Corporation Public Company Limited, or NAM, expects its performance in the second half of 2026 to grow faster than the first half, supported by government budget spending and sales from overseas markets, while targeting net profit of 380 million baht by 2028. Chief Executive Officer Viroj Chaiterdkiet said during an earnings call that third-quarter 2026 revenue is expected to be higher than the second quarter of 2026, and profit margins should improve thanks to lower production costs. The company has prepared a capital expenditure budget of 150 million baht this year, comprising 40 million baht for acquisitions, 20 million baht for research and development, 20 million baht for medical service projects, 5 million baht for solar installation, and 10 million baht for installing robotic arms in the production system, as well as other projects at 5 million baht each. The company aims to increase the proportion of revenue from overseas to 10 percent within the next two to three years, from about 5 percent currently, by expanding distribution channels in Malaysia, Italy, and Indonesia.

Namwiwat Medical Corporation Public Company Limited, or NAM, reported second quarter 2026 profit of 29.503 million baht, up from 12.451 million baht in the same quarter last year. Profit for the first six months of 2026 was 32.191 million baht, down from 52.455 million baht in the same period of 2025. Earnings per share for the quarter were 0.0422 baht, compared with 0.0179 baht a year earlier, and for the six-month period were 0.054 baht, compared with 0.105 baht. The auditor's report on the financial statements was unqualified.

PTT and NAM have signed a purchase agreement for enzymatic medical instrument cleaning solution, aiming to elevate the standards of Thai medical products and advance research toward commercial application. The product uses multi-enzyme technology to enhance cleaning efficiency for various types of medical instruments, has passed international standard testing, and prioritizes safety and environmental considerations. This collaboration seeks to reduce reliance on imports and strengthen the long-term competitiveness of Thailand's life science industry.

NAM has established a subsidiary in Italy named Sterion Italia S.r.l., with 100% ownership and registered capital of 20 million baht, to serve as a base for penetrating the European market and developing products that meet the region's high safety standards. Thailand remains the main production base, with positive results expected in the next two to three years. In the ASEAN market, the company exports to Malaysia and has begun SKD operations in Indonesia, while considering additional direct investment in the future. Currently, foreign revenue accounts for only 5% and is expected to increase significantly over the next three to five years. The company still targets total revenue growth of at least 10% this year from the previous year's 1.886 billion baht.